Atara Biotherapeutics(ATRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATRA Atara Biotherapeutics

Market Closed 12-12 16:00:00 EST

18.00

+0.18

+0.98%

盘后18.00

+0.000.00%

17:58 EST

High18.17	Low16.65	Vol103.35K
Open17.82	D1 Closing17.82	Amplitude8.51%
Mkt Cap129.75M	Tradable Cap82.94M	Total Shares7.21M
T/O1.81M	T/O Rate2.24%	Tradable Shares4.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATRA","market":"US","secType":"STK","nameCN":"Atara Biotherapeutics","latestPrice":17.995,"timestamp":1765573200000,"preClose":17.82,"halted":0,"volume":103345,"hourTrading":{"tag":"盘后","latestPrice":17.995,"preClose":17.995,"latestTime":"17:58 EST","volume":120,"amount":2173.1859,"timestamp":1765580335064},"delay":0,"floatShares":4609000,"shares":7210235,"eps":0.56325,"marketStatus":"Market Closed","change":0.175,"latestTime":"12-12 16:00:00 EST","open":17.82,"high":18.1664,"low":16.65,"amount":1812108.586475,"amplitude":0.085095,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.56325,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1413432000000,"exchange":"NASDAQ","adjPreClose":17.82,"preHourTrading":{"tag":"盘前","latestPrice":18.3222,"preClose":17.82,"latestTime":"08:16 EST","volume":26,"amount":472.57220400000006,"timestamp":1765545371208},"postHourTrading":{"tag":"盘后","latestPrice":17.995,"preClose":17.995,"latestTime":"17:58 EST","volume":120,"amount":2173.1859,"timestamp":1765580335064},"volumeRatio":1.234760395021941,"impliedVol":0.0156,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ATRA","defaultTab":"news","newsList":[{"id":"2585175531","title":"Atara Biotherapeutics Inc : Mizuho Raises Target Price to $18 From $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2585175531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585175531?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:33","pubTimestamp":1763724831,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WX0G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2585157897","title":"Atara Biotherapeutics price target raised to $18 from $16 at Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157897","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157897?lang=en_us&edition=fundamental","pubTime":"2025-11-21 03:45","pubTimestamp":1763667919,"startTime":"0","endTime":"0","summary":"Mizuho analyst Salim Syed raised the firm’s price target on Atara Biotherapeutics (ATRA) to $18 from $16 and keeps an Outperform rating on the shar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atara-biotherapeutics-price-target-raised-to-18-from-16-at-mizuho-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atara-biotherapeutics-price-target-raised-to-18-from-16-at-mizuho-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","ATRA"],"gpt_icon":0},{"id":"2584059369","title":"Top Executives Make Significant Moves with Atara Biotherapeutics Stock!","url":"https://stock-news.laohu8.com/highlight/detail?id=2584059369","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584059369?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:12","pubTimestamp":1763604774,"startTime":"0","endTime":"0","summary":"New insider activity at Atara Biotherapeutics ( ($ATRA) ) has taken place on November 19, 2025. In recent transactions involving Atara Biotherapeut...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executives-make-significant-moves-with-atara-biotherapeutics-stock-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executives-make-significant-moves-with-atara-biotherapeutics-stock-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2584976063","title":"Atara Biotherapeutics Chief Accounting Officer Yanina Grant-Huerta Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584976063","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584976063?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:55","pubTimestamp":1763589333,"startTime":"0","endTime":"0","summary":"Yanina Grant-Huerta, Chief Accounting Officer of Atara Biotherapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL38MzP7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Atara Biotherapeutics Chief Accounting Officer Yanina Grant-Huerta Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATRA"],"gpt_icon":0},{"id":"2584644000","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584644000","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584644000?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·J & J Snack Fds                                 4Q      1.24        BMO","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLCO","CPRT","TGT","ACM","CING","DLB","WB","BZ","BULL","AREC","BBWI","CGON","ARMK","ATRA","WMT","NVDA","CRGO","ADIL","BV","DY","CRDL","BRBR","ARBE","CRNC","ALLT","ATKR","TCOM","POWL","ANRO","CLSD","AZTA","BNTC","NTES","XP","AS","ATOS","CPA","ZTO","ENTA","VIPS","DE","EARN","ENR","BMA","TBBB","CDLR","AHL"],"gpt_icon":1},{"id":"2583980577","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2583980577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583980577?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:00","pubTimestamp":1763118000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Li Auto Inc. Sp ADR                               3Q       .10. ·J & J Snack Fds                                 4Q      1.24        BMO","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","ATRA","AZTA","CRNC","ANRO","ALLT","BNZI","CLCO","TGT","ARMK","DEFT","BRBR","CRGO","DY","ATOS","CDLR","ACM","BMA","ATKR","CGON","ATAI","NVDA","BBAR","DE","TCOM","NTES","AS","BZ","BV","DLB","WB","AREC","CING","CRDL","LGN","ARBE","BNTC","POWL","BTBT","CPA","BBWI","AHL","CLSD","XP","ZTO"],"gpt_icon":1},{"id":"2582837752","title":"Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582837752","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582837752?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:15","pubTimestamp":1762956944,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $3.45M, consensus $2.74M. The company said, “As previously communicated, Atara continues to actively explore and assess potentia...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atara-biotherapeutics-reports-q3-eps-32c-consensus-67c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atara-biotherapeutics-reports-q3-eps-32c-consensus-67c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATRA"],"gpt_icon":0},{"id":"2582377529","title":"Atara Biotherapeutics reduces workforce by 29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582377529","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582377529?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:15","pubTimestamp":1762956932,"startTime":"0","endTime":"0","summary":"The company said, “In October 2025, Atara announced a reduction in its workforce that impacted approximately 29% of its current employees, retainin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atara-biotherapeutics-reduces-workforce-by-29-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atara-biotherapeutics-reduces-workforce-by-29-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATRA"],"gpt_icon":0},{"id":"2582737210","title":"Atara Biotherapeutics Q3 revenue beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582737210","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582737210?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:08","pubTimestamp":1762956481,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics Q3 revenue beats estimatesOverviewAtara Q3 2025 revenue beats analyst expectations despite a significant year-over-year declineCompany reported a net loss of $4.3 mln for Q3 2025","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2582721743","title":"Atara Biotherapeutics Q3 EPS $(0.32) Beats $(0.86) Estimate, Sales $3.453M Beat $1.398M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582721743","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582721743?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:06","pubTimestamp":1762956388,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.86) by 62.79 percent. This is a 89.08 percent increase over losses of $(2.93) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48802733/atara-biotherapeutics-q3-eps-0-32-beats-0-86-estimate-sales-3-453m-beat-1-398m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA"],"gpt_icon":0},{"id":"2582537254","title":"BRIEF-Atara Biotherapeutics Q3 EPS USD -0.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2582537254","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582537254?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:00","pubTimestamp":1762956046,"startTime":"0","endTime":"0","summary":"BRIEF-Atara Biotherapeutics Q3 EPS USD -0.32\n\n\nNov 12 (Reuters) - Atara Biotherapeutics Q3 operating income USD -3.574 million.\n\nQ3 net income USD -4.303 million\nQ3 revenue USD 3.453 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX8AE45E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2582372580","title":"Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372580?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:00","pubTimestamp":1762956003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUARY16K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATRA"],"gpt_icon":0},{"id":"2582372962","title":"Atara Biotherapeutics Inc: Anticipate Full-Year 2025 Operating Expenses Will Decrease by at Least 60% Compared to 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372962?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:00","pubTimestamp":1762956001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX8AE45E:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2582372535","title":"Atara Biotherapeutics Q3 Revenue USD 3.453 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372535?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:00","pubTimestamp":1762956001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX8AE45E:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2582388013","title":"Top News Today/Canada: Barrick's Interim CEO Gets to Work","url":"https://stock-news.laohu8.com/highlight/detail?id=2582388013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582388013?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:30","pubTimestamp":1762810200,"startTime":"0","endTime":"0","summary":"Barrick Looks to Get Handle on North American Operations, Find Growth. Barrick Mining is diving into how its core gold operations in Nevada are being run and is looking for opportunities to boost production, steps that come after parting ways with its former chief executive.Mark Hill, Barrick's interim CEO, said that the mining company is determined to grow and not just replace the resources it digs up, and to produce gold and copper safely.Since taking on the role and being named chief operating officer in late September, Hill said he has met with Barrick's teams around the world. He also spent several weeks in Nevada, which alongside an asset in the Dominican Republic, is a focus of the company's review.Barrick Looking to Reset Safety Culture  Barrick Continues Efforts to Free Workers Jailed in Mali. Burger King Strikes Joint Venture to Double Presence in China. C2AE offers a range of engineering services to clients including state and local governments, transportation agencies, and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLSN","BK4139","WKHS","MGNX","ATOS","BK4109","BK4079","BK4551","GIFI","BK4023","LU0205194284.USD","MGTX","WHLM","FTHM","CRBU","EVI","BK4021","PVLA","NRDE","BK4179","AMTX","IE00BFMHRM44.USD","BK4505","BK4099","BK4137","CENN","MVIS","ATRA","CLDX","LPTH","GNPX","QUIK","KALV","SND","BK4547","BK4168","PRLD","BK4539","LU0205193047.USD","BK4134","STXS","DOX","SYPR","IPSC","BK4082","BK4138","SSTI","ACCS","NMM"],"gpt_icon":1},{"id":"2581990885","title":"Atara Biotherapeutics Inc  expected to post a loss of 86 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581990885","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581990885?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:40","pubTimestamp":1762522820,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics Inc  expected to post a loss of86cents a share - Earnings Preview Atara Biotherapeutics Inc ATRA.OQ ATRA.O is expected to  show a fall in quarterly revenue when it reports  resul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ1PO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2580596219","title":"FDA Accepts Tabelecleucel BLA for Priority Review with PDUFA Date Set for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2580596219","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580596219?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:02","pubTimestamp":1762178561,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL6LDx2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATRA"],"gpt_icon":0},{"id":"2580219850","title":"Pierre Fabre Pharmaceuticals Announces Transfer From Atara Biotherapeutics of the Biologics License Application (Bla) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Ebv+ Ptld)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219850","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219850?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:00","pubTimestamp":1762178400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA4WRSXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2574155177","title":"Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry","url":"https://stock-news.laohu8.com/highlight/detail?id=2574155177","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574155177?lang=en_us&edition=fundamental","pubTime":"2025-10-09 18:21","pubTimestamp":1760005286,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 30% gain in the last...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atra/atara-biotherapeutics/news/atara-biotherapeutics-inc-nasdaqatra-stock-catapults-30-thou","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atra/atara-biotherapeutics/news/atara-biotherapeutics-inc-nasdaqatra-stock-catapults-30-thou","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","NVIW.SI","PSQ","TQQQ","USAW.SI","TSYW.SI","QLD","ATRA","USJW.SI","SQQQ","MNQmain",".IXIC","NQmain","QID"],"gpt_icon":1},{"id":"2573961227","title":"BUZZ-Atara rises on plan to lay off staff","url":"https://stock-news.laohu8.com/highlight/detail?id=2573961227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573961227?lang=en_us&edition=fundamental","pubTime":"2025-10-08 00:10","pubTimestamp":1759853433,"startTime":"0","endTime":"0","summary":"BUZZ-Atara rises on plan to lay off staff** Cell therapy developer Atara's ATRA.O shares rise 5.1% to $14.69, its highest in more than eight months** Co to lay off 29% of staff, retaining about 15 employees** ATRA expects to complete cuts by Jan 2026 ** Co expects ~$1.3 mln in layoff costs related to severance and other benefits ** Company says more charges may arise depending on events tied to layoffs** Including session's move, stock up ~10% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nL3N3VO0YY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atarabio.com","stockEarnings":[{"period":"1week","weight":0.2558},{"period":"1month","weight":0.4431},{"period":"3month","weight":0.4847},{"period":"6month","weight":1.0402},{"period":"1year","weight":0.6434},{"period":"ytd","weight":0.352}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.079335},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.062727},{"month":3,"riseRate":0.454545,"avgChangeRate":0.043828},{"month":4,"riseRate":0.181818,"avgChangeRate":-0.039343},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.070861},{"month":6,"riseRate":0.636364,"avgChangeRate":0.068043},{"month":7,"riseRate":0.636364,"avgChangeRate":0.002868},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.029857},{"month":9,"riseRate":0.727273,"avgChangeRate":0.031685},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.093327},{"month":11,"riseRate":0.833333,"avgChangeRate":0.232545},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.068938}],"exchange":"NASDAQ","name":"Atara Biotherapeutics","nameEN":"Atara Biotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atara Biotherapeutics(ATRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atara Biotherapeutics(ATRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atara Biotherapeutics,ATRA,Atara Biotherapeutics股票,Atara Biotherapeutics股票老虎,Atara Biotherapeutics股票老虎国际,Atara Biotherapeutics行情,Atara Biotherapeutics股票行情,Atara Biotherapeutics股价,Atara Biotherapeutics股市,Atara Biotherapeutics股票价格,Atara Biotherapeutics股票交易,Atara Biotherapeutics股票购买,Atara Biotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atara Biotherapeutics(ATRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atara Biotherapeutics(ATRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}